IMMUNOTHERAPY

This study compares two treatment approaches for people with operable head and neck squamous cell carcinoma. One group receives low-dose radiotherapy plus targeted therapy and immunotherapy before surgery, while the other gets only targeted therapy and immunotherapy. The goal is …

This phase 2 trial is testing whether a combination of chemotherapy (mFOLFOX6), a targeted therapy (bevacizumab), and an immunotherapy (PD-1 inhibitor) can help people with a specific type of locally advanced colorectal cancer called microsatellite stable (MSS). Unlike other colo…

This study tested a combination of two drugs, tislelizumab and anlotinib, in 29 people with advanced pulmonary pleomorphic carcinoma, a rare and aggressive lung cancer. The goal was to see if the combo could shrink tumors or slow the disease. Participants had stage III or IV canc…

This study tests whether adding an immunotherapy drug called lorigerlimab to standard chemotherapy (docetaxel) can help men with a tough-to-treat type of prostate cancer live longer without their disease getting worse. About 150 men with metastatic castration-resistant prostate c…

This study tested a treatment called oral immunotherapy for people with shrimp allergy. 20 participants aged 12-40 with confirmed shrimp allergy were given increasing amounts of shrimp over time to see if they could tolerate more shrimp without a reaction. The main goal was to me…

This completed Phase 2 trial tested whether a special DNA-based test could predict how well patients with stomach or rectal cancer respond to immunotherapy (tislelizumab) combined with chemotherapy and/or radiation. 189 adults with advanced cancer participated. The goal was to se…

This phase 2 trial tested whether giving the chemotherapy drug dacarbazine (DTIC) before re-trying immunotherapy could help patients with advanced melanoma whose cancer had stopped responding to immunotherapy. The study enrolled 38 adults with metastatic melanoma that had progres…

This study tested whether adding immunotherapy to standard chemoradiation before surgery helps people with a specific type of ultra-low rectal cancer (MSS type). The goal was to increase the chance of a complete response, meaning the tumor disappears, and to preserve the anus and…

This early-phase trial tested a personalized immunotherapy for people with advanced solid tumors. Doctors removed a sample of each patient's tumor, grew the immune cells (TILs) in a lab, and then infused them back along with another drug. The goal was to see if this approach is s…

This phase 2 trial tested the drug serplulimab (an immunotherapy) combined with standard chemotherapy in 30 people with stage II-IIIA non-small cell lung cancer that could be surgically removed. The treatment was given before and after surgery to see if it could shrink tumors and…

This study observed 255 cancer patients receiving immunotherapy to understand why some develop skin side effects. Researchers measured immune markers and lipids in the skin and blood. The goal is to identify patterns that could predict or explain these reactions.

This study created and tested an educational website to help Black and African American cancer patients learn about personalized cancer treatments and clinical trials. Researchers interviewed 48 patients and caregivers, then tested the website with 33 patients. The goal was to se…

This study looked at 42 adults with advanced solid tumors who were already on or about to start checkpoint inhibitor immunotherapy and also needed palliative radiotherapy for symptom relief. Researchers wanted to see if the combination was safe (less than 30% severe side effects)…

This study followed 44 adults with leukemia or lymphoma who received CAR T-cell therapy to see how their hearts were affected. Researchers used heart scans, blood tests, and quality-of-life surveys before and after treatment. The goal was to learn how often heart problems occur a…